26th October 2016

Luxury & Consumer Goods

Groupe SEB

Price EUR132.50

Bloomberg Reuters 12-month High / Low (EUR) Market Cap (EUR) Ev (BG Estimates) (EUR) Avg. 6m daily volume (000) 3y EPS CAGR			SK FP SEBF.PA 132.5 / 81.9 6,647 8,817 52.70 25.4%	
	1 M	3 M	6 M 31	L/12/15
Absolute perf.	5.6%	8.0%	49.7%	40.1%
Consumer Gds	-2.4%	-2.3%	-0.4%	-3.5%
DJ Stoxx 600	-0.7%	0.6%	-1.0%	-6.2%
YEnd Dec. (€m)	2015	2016e	2017e	2018e
Sales	4,770	5,337	6,420	6,737
% change		11.9%	20.3%	4.9%
Adj. EBIT	428	517.7	664.9	717.4
EBIT	396.6	482.6	622.6	673.1
% change		21.7%	29.0%	8.1%
Net income	205.9	265.4	357.5	406.5
% change		28.9%	34.7%	13.7%
	2015	2016e	2017e	2018e
EBIT margin	8.3	9.0	9.7	10.0
Net margin	4.3	5.0	5.6	6.0
ROE	13.2	18.1	20.4	19.8
ROCE	12.8	8.9	10.7	11.5
Gearing	16.5	119.9	99.7	74.9
(€)	2015	2016e	2017e	2018e
EPS	4.14	5.34	7.19	8.18
% change	-	28.9%	34.7%	13.7%
P/E	32.0x	24.8x	18.4x	16.2x
FCF yield (%)	4.8%	3.4%	3.9%	6.1%
Dividends (€)	1.54	1.65	1.85	2.05
Div yield (%)	1.2%	1.2%	1.4%	1.5%
EV/Sales	1.5x	1.7x	1.4x	1.2x
EV/EBITDA	16.3x	17.0x	13.0x	11.7x
EV/EBIT	17.6x	18.1x	13.8x	12.4x



And the beat goes on!

Fair Value EUR140 vs. EUR132 (+6%)

Yesterday Groupe SEB unveiled Q3 sales of EUR1,204m (CS: EUR1,195m), up 6.8% reported on betterthan expected LFL growth (+6.5% vs. CS of 5.4%e). The adj. EBIT reached EUR140m and topped expectations by 8%, representing 130bp-margin improvement to 11.6%. Against this favourable momentum, the Group raises its FY sales and adj. EBIT targets. We raise our FY16 estimates on SEB stand-alone (acquisition of WMF should be completed by the end of November), leading to our new FV of EUR140 vs EUR132 initially. Buy recommendation confirmed.

ANALYSIS

- Q3 sales up 6.8% to EUR1,204m. Although sales were in line with the CS (1,195m), the LFL growth beat expectations (+6.5% vs. +5.4%e), showing a consistent performance over the first 9M (+6.2%). The scope effect amounted to 2% (OBH Nordica and EMSA) whilst the FX headwind eased off (-1.7% vs. -4.3% in H1).
- Solid growth in EMEA (+6.9% LFL). Western Europe was up 4.6%, again driven by France (+4.6%) which achieved its 13th consecutive quarter of growth in both SDA and cookware. Sales grew in double-digits in Germany and in Italy, whilst trends were softer in Spain (LP activity last year) and in the UK. In Other Countries (+13.1% LFL), sales in Russia continued to be robust (helped by a LP), as well as in the Middle-East.
- Gradual recovery in the Americas (+2% vs. -5.4% in H1). This improvement occurred in both regions: in North America (+1.4% vs. -9.5%), the US activity recovers from the destocking phase that affected H1 and the sales decline in Canada was reversed thanks to aggressive initiatives (marketing, promotional activity). In Latin America (+3% vs. +0.4%), trends in Brazil have relatively improved (slight decline vs. -15% in Q2) in challenging market conditions, but the Group was affected by transportation strikes in Colombia.
- Strong momentum in Asia-Pacific (+9.5% LFL). As announced at H1 results, the 23.5% uplift in China over Q2 was partly driven by early shipments to anticipate the temporary closure of one of Supor's plants. Hence the sales "only" grew by 10.2% in Q3, but the 9M performance (+15%) gives a reliable picture of SEB's underlying trends in this market. Sales in Japan and South Korea continued to enjoy a solid development.
- Adj. EBIT (EUR140m) topped expectations by 8% (CS: EUR130m). As a consequence, the adj. margin expanded 130bp to 11.6% thanks to a positive price-mix that more than offset the FX headwind (EUR43m). The step up in marketing expenses was also offset by other tailwinds (sourcing, efficiency gains).
- Groupe SEB raises FY16 outlook: (i) LFL growth of 6% after 6.2% in 9M (previous guidance: "exceed 5%") and (ii) the adj. EBIT is expected to increase by 15% reported after +19% in 9M (previous target: "above 10%"). We consider this guidance to be a bit conservative as it would only imply +9% growth over Q4. Even if SEB accelerates further marketing expenses in Q4, we believe that the Group could keep a faster pace of growth. Groupe SEB still guides on a negative FX impact of EUR120m for this year. Prior to yesterday's publication, the CS was anticipating LFL growth of 5.8% and 13% growth of the adj. EBIT.
- We raise our FY16 assumptions by ~3%. We nudge up our LFL growth forecast to 6.1% vs. 5.6%, implying +6% in Q4. As for our adj. EBIT estimate, we increase it by ~2.5% to reflect the revised guidance as well as the better-than-expected 9M performance.
- WMF acquisition expected to be completed by the end of November. CFO Vincent Leonard confirmed that the operation is currently reviewed by the European Commission and its approval might be announced before the end of November. Hence WMF should be consolidated from December 2016. It is worth noting that our current FY16-17 assumptions are based on a consolidation starting in October, which would require some adjustments from our side in the coming weeks, but with no material impact on our valuation.

VALUATION

 In light of this solid performance and revised guidance, we expect a positive market reaction today even if the stock has already rallied ~40% ytd. Besides the solid underlying trends, we believe that investors' attention will now mainly be on the successful integration of WMF, which will be a key catalyst for next year.

(To be continued next page)

BRYAN, GARNIER & CO

BUY

NEXT CATALYSTS

FY16 Sales to be released by the end of January 2017. •

Click here to download document

Q1 sales by region (new reporting):

EURm	Q3 16	LFL growth (%)	9M 16	LFL growth (%)
EMEA – Western	416	4.6	1,148	4.7
EMEA – Others	154	13.1	438	9.6
Total EMEA	570	6.9	1,586	6.1
North America	160	1.4	374	-5.3
South America	105	3.0	243	1.4
Americas	265	2.0	617	-2.6
China	259	10.2	844	14.9
Rest of Asia	110	7.6	321	4.3
Asia-Pacific	369	9.5	1,165	11.9
Total Groupe SEB	1,204	6.5	3,368	6.2
Source: Company Data				



Analyst : Cédric Rossi 33(0) 1 70 36 57 25 crossi@bryangarnier.com Sector Team : Nikolaas Faes Loïc Morvan Antoine Parison Virginie Roumage

BRYAN, GARNIER & CO

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a				
Der	recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of				
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock				
	will feature an introduction outlining the key reasons behind the opinion.				

- NEUTRAL Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
- SELL Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 57,3%

NEUTRAL ratings 31,2%

SELL ratings 11,5%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	holding Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	
2	Issuer shareholding in Bryan Garnier	Bryan The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	
6	Investment banking agreement A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.		No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

BRYAN, GARNIER & CO

London	Paris	New York	Munich	New Delhi	
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath	
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich	New Delhi 110 001 Tel +91 11 4132 6062	
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	+91 98 1111 5119	
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	Fax +91 11 2621 9062	
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Geneva	
Authorised and regulated by the	nancial Conduct Authority (FCA) and the			rue de Grenus 7 CP 2113	
Financial Conduct Authority (FCA)	Autorité de Contrôle prudential et de			Genève 1, CH 1211	
	resolution (ACPR)			Tel +4122 731 3263	

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Fax+4122731 3243 Regulated by the FINMA

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm or an associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited and should not rely on it for any purposes whatsoever.

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not

aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.

BRYAN, GARNIER & CO